article thumbnail

STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more

STAT

Back in 2004, Gilead explained its decision by maintaining the medicines were not sufficiently different, but internal documents produced in court suggested the company made this move in order to maximize profits. Topline data are expected late this year.

article thumbnail

Why Balancing Blood Sugar is Vital for Hashimoto’s Health

The Thyroid Pharmacist

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CHMP meeting highlights – July 2022

European Pharmaceutical Review

The committee adopted a positive opinion for Mounjaro (tirzepatide) for the treatment of adults with type 2 diabetes mellitus. Vabysmo (faricimab), intended for the treatment of adults with neovascular age-related macular degeneration and visual impairment due to diabetic macular oedema, received a positive opinion from the Committee.

article thumbnail

Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol

pharmaphorum

healthcare facilities were found to have an EHR system fully implemented by 2004. Prior to HelpAround, Knobel was Head of Mobile at AgaMatrix Diabetes, maker of the world’s first smartphone glucometer. The Institute of Medicine first advocated a shift from paper-based to electronic medical records in 1992 , yet, only 13% of U.S.

HIPAA 98
article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

Stock Exchange: NYSE Novo Nordisk is a global healthcare biopharma company focusing on its mission to drive change and fight against diabetes and other serious chronic diseases such as obesity, rare blood, and rare endocrine diseases. R&D Expenditure: $3.5B

article thumbnail

How Myo-inositol Can Improve Hashimoto’s Symptoms

The Thyroid Pharmacist

Myo-inositol has been found to provide many valuable health effects, including anti-inflammatory, anti-oxidant, anti-diabetic, and anticancer effects. (7). They also concluded that patients testing with positive thyroid antibodies should be followed closely for diabetes mellitus and cardiovascular events. (1)

article thumbnail

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

PharmaShots

in the year 2004, depicting a growth of 17% from 2003 with cost savings and synergies from the prior acquisition of Pharmacia. Following its patent expiry, Cipro’s sales in the year 2004 declined by 12.9% Bayer’s Matetial Science subgroup moved ahead effectively in 2004 showing a rise of 15.3%